Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Strides Pharma Science Ltd indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating reflects a balance between the company’s strengths and challenges, signalling that while the stock has potential, it also carries certain risks that warrant caution. The rating was revised from 'Sell' to 'Hold' on 06 April 2026, following a notable improvement in the company’s overall mojo score, which rose from 40 to 56 points.
How the Stock Looks Today: Quality Assessment
As of 15 July 2026, Strides Pharma Science Ltd’s quality grade remains below average. The company’s long-term fundamental strength is relatively weak, with an average Return on Capital Employed (ROCE) of 8.83%. This figure suggests that the company is generating modest returns on the capital invested in its operations. Over the past five years, net sales have grown at an annual rate of 7.94%, while operating profit has increased by 11.02% annually. Although these growth rates indicate steady expansion, they fall short of the robust growth typically favoured by investors seeking high-quality stocks.
Additionally, the company’s ability to service its debt is a concern, with a Debt to EBITDA ratio of 1.90 times. This relatively high leverage ratio implies that the company carries a significant debt burden compared to its earnings before interest, taxes, depreciation, and amortisation, which could constrain financial flexibility in adverse market conditions.
Valuation: Attractive but with Caveats
Currently, Strides Pharma Science Ltd’s valuation is considered attractive. The stock trades at an Enterprise Value to Capital Employed ratio of 2.5, which is lower than the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. This discount suggests that the market may be undervaluing the company relative to its capital base.
Despite this, investors should note that while the stock has delivered a return of 18.17% over the past year as of 15 July 2026, the company’s profits have declined by 14.9% during the same period. This divergence between stock price appreciation and profit contraction highlights a potential disconnect that investors need to monitor closely.
Financial Trend: Positive Momentum Amid Challenges
The financial trend for Strides Pharma Science Ltd is very positive as of today. The company reported a remarkable 54.96% growth in net profit in its most recent quarter ending March 2026. This marks the eleventh consecutive quarter of positive results, underscoring a sustained improvement in operational performance.
Key financial ratios reinforce this positive trend. The operating profit to interest coverage ratio stands at a healthy 5.77 times, indicating strong earnings relative to interest expenses. The half-year ROCE has reached a high of 17.96%, reflecting improved capital efficiency. Furthermore, the debt-equity ratio has decreased to 0.57 times, signalling a reduction in financial leverage and enhanced balance sheet strength.
These metrics suggest that the company is on a firmer financial footing, with improving profitability and reduced risk from debt obligations, which supports the current 'Hold' rating.
Technical Outlook: Mildly Bullish Signals
From a technical perspective, Strides Pharma Science Ltd exhibits mildly bullish characteristics. The stock has shown resilience with a 6-month return of 14.19% and a year-to-date gain of 18.91% as of 15 July 2026. Shorter-term movements include a modest 0.33% increase on the latest trading day, reflecting steady investor interest.
However, the stock’s price has experienced some volatility, with a 1-month decline of 1.14% and a 1-week dip of 0.61%. These fluctuations suggest that while the technical momentum is positive, investors should remain cautious of potential short-term corrections.
Risks to Consider: Promoter Share Pledging
One notable risk factor is the high level of promoter share pledging, with 27.27% of promoter shares currently pledged. In volatile or falling markets, this can exert additional downward pressure on the stock price, as pledged shares may be liquidated to meet margin calls. Investors should factor this into their risk assessment when considering exposure to Strides Pharma Science Ltd.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Summary for Investors
In summary, Strides Pharma Science Ltd’s 'Hold' rating reflects a nuanced view of the company’s current position. The stock offers an attractive valuation and is supported by positive financial trends, including strong recent profit growth and improved debt metrics. However, the company’s below-average quality grade, modest long-term growth, and significant promoter share pledging temper enthusiasm.
Investors considering Strides Pharma Science Ltd should weigh these factors carefully. The 'Hold' rating suggests that while the stock is not a compelling buy at present, it is also not a sell candidate. It may be suitable for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a moderate risk appetite, who are willing to monitor the company’s progress and market conditions closely.
Looking Ahead
Going forward, key indicators to watch include the company’s ability to sustain profit growth, further reduce leverage, and improve its long-term return metrics. Additionally, any changes in promoter share pledging levels and broader sector dynamics will influence the stock’s outlook. Maintaining a balanced portfolio approach and staying informed on quarterly results will be essential for investors navigating this stock.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
